{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:52:41Z","timestamp":1793757161809,"version":"4.6.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002367","name":"Chinese Academy of Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002367","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21977105"],"award-info":[{"award-number":["21977105"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22107111"],"award-info":[{"award-number":["22107111"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32000890"],"award-info":[{"award-number":["32000890"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32171220"],"award-info":[{"award-number":["32171220"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.bcp.2023.115746","type":"journal-article","created":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T18:32:30Z","timestamp":1691865150000},"page":"115746","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Otilonium Bromide acts as a selective USP28 inhibitor and exhibits cytotoxic activity against multiple human cancer cell lines"],"prefix":"10.1016","volume":"215","author":[{"given":"Zhuo","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiluan","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengying","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naixia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2013-5511","authenticated-orcid":false,"given":"Li","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.bcp.2023.115746_b0005","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.3390\/cancers15041112","article-title":"Autophagy\/mitophagy regulated by ubiquitination: a promising pathway in cancer therapeutics","volume":"15","author":"Jee","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.bcp.2023.115746_b0010","doi-asserted-by":"crossref","first-page":"20","DOI":"10.2174\/1871520620666200811114159","article-title":"The ubiquitin-proteasome pathway and epigenetic modifications in cancer","volume":"21","author":"Yerlikaya","year":"2021","journal-title":"Anticancer Agents Med. Chem."},{"issue":"15","key":"10.1016\/j.bcp.2023.115746_b0015","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1074\/jbc.TM117.000117","article-title":"Ubiquitin signaling and autophagy","volume":"293","author":"Grumati","year":"2018","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.bcp.2023.115746_b0020","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/cr.2016.39","article-title":"Ubiquitin modifications","volume":"26","author":"Swatek","year":"2016","journal-title":"Cell Res."},{"issue":"6","key":"10.1016\/j.bcp.2023.115746_b0025","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1083\/jcb.201902074","article-title":"Post-translational regulation of ubiquitin signaling","volume":"218","author":"Song","year":"2019","journal-title":"J. Cell Biol."},{"issue":"8","key":"10.1016\/j.bcp.2023.115746_b0030","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nrm2731","article-title":"Breaking the chains: structure and function of the deubiquitinases","volume":"10","author":"Komander","year":"2009","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"6","key":"10.1016\/j.bcp.2023.115746_b0035","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41580-019-0099-1","article-title":"Breaking the chains: deubiquitylating enzyme specificity begets function","volume":"20","author":"Clague","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.bcp.2023.115746_b0040","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/ng.3166","article-title":"Mutations in the deubiquitinase gene USP8 cause Cushing's disease","volume":"47","author":"Reincke","year":"2015","journal-title":"Nat. Genet."},{"issue":"14","key":"10.1016\/j.bcp.2023.115746_b0045","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14143547","article-title":"Deubiquitinases in cancers: aspects of proliferation, metastasis, and apoptosis","volume":"14","author":"Liu","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bcp.2023.115746_b0050","doi-asserted-by":"crossref","first-page":"3481371","DOI":"10.1155\/2016\/3481371","article-title":"Deubiquitinases: novel therapeutic targets in immune surveillance?","volume":"2016","author":"Lopez-Castejon","year":"2016","journal-title":"Mediators Inflamm."},{"issue":"1","key":"10.1016\/j.bcp.2023.115746_b0055","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41380-021-01233-8","article-title":"Deubiquitinating enzymes (DUBs): decipher underlying basis of neurodegenerative diseases","volume":"27","author":"Liu","year":"2022","journal-title":"Mol. Psychiatry"},{"issue":"2","key":"10.1016\/j.bcp.2023.115746_b0060","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41419-017-0208-z","article-title":"Targeting deubiquitinase USP28 for cancer therapy","volume":"9","author":"Wang","year":"2018","journal-title":"Cell Death Dis."},{"issue":"10","key":"10.1016\/j.bcp.2023.115746_b0065","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.3390\/cells10102652","article-title":"USP28: oncogene or tumor suppressor? a unifying paradigm for squamous cell carcinoma","volume":"10","author":"Prieto-Garcia","year":"2021","journal-title":"Cells"},{"issue":"7","key":"10.1016\/j.bcp.2023.115746_b0070","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1158\/0008-5472.CAN-14-1726","article-title":"Usp28 counteracts Fbw7 in intestinal homeostasis and cancer","volume":"75","author":"Diefenbacher","year":"2015","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.bcp.2023.115746_b0075","doi-asserted-by":"crossref","first-page":"e11101","DOI":"10.15252\/emmm.201911101","article-title":"Maintaining protein stability of \u0394Np63 via USP28 is required by squamous cancer cells","volume":"12","author":"Prieto-Garcia","year":"2020","journal-title":"EMBO Mol. Med."},{"issue":"1","key":"10.1016\/j.bcp.2023.115746_b0080","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.celrep.2013.08.030","article-title":"The deubiquitinase USP28 stabilizes LSD1 and confers stem-cell-like traits to breast cancer cells","volume":"5","author":"Wu","year":"2013","journal-title":"Cell Rep."},{"issue":"7","key":"10.1016\/j.bcp.2023.115746_b0085","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/ncb1601","article-title":"The ubiquitin-specific protease USP28 is required for MYC stability","volume":"9","author":"Popov","year":"2007","journal-title":"Nat. Cell Biol."},{"issue":"17","key":"10.1016\/j.bcp.2023.115746_b0090","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1002\/1878-0261.13217","article-title":"USP28 enables oncogenic transformation of respiratory cells, and its inhibition potentiates molecular therapy targeting mutant EGFR, BRAF and PI3K","volume":"16","author":"Prieto-Garcia","year":"2022","journal-title":"Mol. Oncol."},{"issue":"8","key":"10.1016\/j.bcp.2023.115746_b0095","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.apsb.2019.12.008","article-title":"Discovery of [1,2,3]triazolo[4,5-d]pyrimidine derivatives as highly potent, selective, and cellularly active USP28 inhibitors","volume":"10","author":"Liu","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.bcp.2023.115746_b0100","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/s41392-022-01209-2","article-title":"Identification of a class of potent USP25\/28 inhibitors with broad-spectrum anti-cancer activity","volume":"7","author":"Peng","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bcp.2023.115746_b0105","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.71596","article-title":"USP28 deletion and small-molecule inhibition destabilizes c-MYC and elicits regression of squamous cell lung carcinoma","volume":"10","author":"Ruiz","year":"2021","journal-title":"Elife"},{"issue":"12","key":"10.1016\/j.bcp.2023.115746_b0110","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1021\/acschembio.7b00334","article-title":"Identification and characterization of dual inhibitors of the USP25\/28 deubiquitinating enzyme subfamily","volume":"12","author":"Wrigley","year":"2017","journal-title":"ACS Chem. Biol."},{"issue":"2","key":"10.1016\/j.bcp.2023.115746_b0115","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1006\/phrs.1998.0340","article-title":"Receptor binding profile of Otilonium bromide","volume":"38","author":"Evangelista","year":"1998","journal-title":"Pharmacol. Res."},{"issue":"2","key":"10.1016\/j.bcp.2023.115746_b0120","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1042\/BJ20150088","article-title":"The N-terminal ubiquitin-binding region of ubiquitin-specific protease 28 modulates its deubiquitination function: NMR structural and mechanistic insights","volume":"471","author":"Wen","year":"2015","journal-title":"Biochem. J"},{"issue":"11","key":"10.1016\/j.bcp.2023.115746_b0125","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/nsmb.3475","article-title":"Mechanism and regulation of the Lys6-selective deubiquitinase USP30","volume":"24","author":"Gersch","year":"2017","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"4","key":"10.1016\/j.bcp.2023.115746_b0130","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1111\/febs.15461","article-title":"USP28 and USP25 are downregulated by Vismodegib in vitro and in colorectal cancer cell lines","volume":"288","author":"Wang","year":"2021","journal-title":"FEBS J."},{"key":"10.1016\/j.bcp.2023.115746_b0135","doi-asserted-by":"crossref","unstructured":"R. Valero, M. Bayes, M. Francisca Sanchez-Font, O. Gonzalez-Angulo, R. Gonzalez-Duarte, G. Marfany, Characterization of alternatively spliced products and tissue-specific isoforms of USP28 and USP25, Genome Biol. 2(10) (2001) RESEARCH0043.","DOI":"10.1186\/gb-2001-2-10-research0043"},{"issue":"8","key":"10.1016\/j.bcp.2023.115746_b0140","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1172\/JCI73733","article-title":"The deubiquitinase USP28 controls intestinal homeostasis and promotes colorectal cancer","volume":"124","author":"Diefenbacher","year":"2014","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.bcp.2023.115746_b0145","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41525-021-00226-4","article-title":"The landscape of driver mutations in cutaneous squamous cell carcinoma","volume":"6","author":"Chang","year":"2021","journal-title":"NPJ Genom. Med."},{"key":"10.1016\/j.bcp.2023.115746_b0150","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1074\/jbc.RA120.014479","article-title":"The 89-kDa PARP1 cleavage fragment serves as a cytoplasmic PAR carrier to induce AIF-mediated apoptosis","volume":"296","author":"Mashimo","year":"2021","journal-title":"J. Biol. Chem."},{"issue":"19","key":"10.1016\/j.bcp.2023.115746_b0155","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.4161\/cc.6.19.4804","article-title":"Fbw7 and Usp28 regulate myc protein stability in response to DNA damage","volume":"6","author":"Popov","year":"2007","journal-title":"Cell Cycle"},{"issue":"3","key":"10.1016\/j.bcp.2023.115746_b0160","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41418-021-00875-z","article-title":"Inhibition of USP28 overcomes Cisplatin-resistance of squamous tumors by suppression of the Fanconi anemia pathway","volume":"29","author":"Prieto-Garcia","year":"2022","journal-title":"Cell Death Differ."},{"issue":"10","key":"10.1016\/j.bcp.2023.115746_b0165","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1101\/gad.300889.117","article-title":"USP25 regulates Wnt signaling by controlling the stability of tankyrases","volume":"31","author":"Xu","year":"2017","journal-title":"Genes Dev."},{"issue":"5","key":"10.1016\/j.bcp.2023.115746_b0170","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1177\/030006059902700501","article-title":"Otilonium bromide: a selective spasmolytic for the gastrointestinal tract","volume":"27","author":"Evangelista","year":"1999","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.bcp.2023.115746_b0175","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ejmech.2023.115369","article-title":"Structure-based discovery of potent USP28 inhibitors derived from Vismodegib","volume":"254","author":"Zhou","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2023.115746_b0180","doi-asserted-by":"crossref","first-page":"102154","DOI":"10.1016\/j.ctrv.2021.102154","article-title":"MYC as a target for cancer treatment","volume":"94","author":"Duffy","year":"2021","journal-title":"Cancer Treat. Rev."},{"issue":"16","key":"10.1016\/j.bcp.2023.115746_b0185","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.2174\/1381612824666180507122935","article-title":"Otilonium bromide: a drug with a complex mechanism of action","volume":"24","author":"Evangelista","year":"2018","journal-title":"Curr. Pharm. Des."},{"issue":"10","key":"10.1016\/j.bcp.2023.115746_b0190","doi-asserted-by":"crossref","first-page":"e0044321","DOI":"10.1128\/AAC.00443-21","article-title":"Irritable bowel syndrome therapeutic has broad-spectrum antimicrobial activity","volume":"65","author":"Cunningham","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bcp.2023.115746_b0195","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.neuro.2018.11.003","article-title":"Otilonium and pinaverium trigger mitochondrial-mediated apoptosis in rat embryo cortical neurons in vitro","volume":"70","author":"Garcia-Alvarado","year":"2019","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.bcp.2023.115746_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2019.101912","article-title":"Molecular insight of regorafenib treatment for colorectal cancer","volume":"81","author":"Arai","year":"2019","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bcp.2023.115746_b0205","doi-asserted-by":"crossref","unstructured":"A. Grothey, E. Van Cutsem, A. Sobrero, S. Siena, A. Falcone, M. Ychou, Y. Humblet, O. Bouche, L. Mineur, C. Barone, A. Adenis, J. Tabernero, T. Yoshino, H.J. Lenz, R.M. Goldberg, D.J. Sargent, F. Cihon, L. Cupit, A. Wagner, D. Laurent, C.S. Group, Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial, Lancet 381(9863) (2013) 303\u2013312.","DOI":"10.1016\/S0140-6736(12)61900-X"},{"issue":"22","key":"10.1016\/j.bcp.2023.115746_b0210","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.2217\/fon-2017-0512","article-title":"Regorafenib in the treatment of metastatic colorectal cancer","volume":"14","author":"de la Fouchardiere","year":"2018","journal-title":"Future Oncol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295223003374?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295223003374?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:54:20Z","timestamp":1757771660000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295223003374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":42,"alternative-id":["S0006295223003374"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2023.115746","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Otilonium Bromide acts as a selective USP28 inhibitor and exhibits cytotoxic activity against multiple human cancer cell lines","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2023.115746","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115746"}}